Eli Lilly and Company-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 12, pp. 1407-1418